呼吁建立新辅助性癌联盟:从其他癌症类型中吸取教训
Axel Bex1, Michael Jewett2, Bryan Lewis3
1Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK.
新辅助性全身治疗改善了许多癌症的结果,但对于细胞癌 (RCC) 尚未改善. 国际合作对于为高风险RCC患者开发适应性术后免疫治疗策略至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞癌研究 细胞癌研究
背景情况:
- 新辅助性全身疗法在改善各种固体瘤的结果方面取得了显著的成功.
- 然而,这种治疗进步尚未转化为对细胞癌 (RCC) 的可比益处.
研究的目的:
- 为突出改善细胞癌的新辅助策略的未满足需求.
- 强调建立共识和国际合作的必要性,以推进RCC的外科手术期免疫疗法.
主要方法:
- 综述目前在固体瘤中新辅助治疗结果.
- 对将这些策略应用于细胞癌的局限性和挑战进行分析.
主要成果:
- 新辅助性全身治疗没有在细胞癌 (RCC) 中显著改善结局.
- 在对RCC的术后免疫疗法的有效应用方面存在差距.
结论:
- 迫切需要达成共识和国际合作,为RCC开发适应性术后免疫治疗策略.
- 专注于复发高风险的患者对于推进RCC治疗至关重要.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Tumor Immunotherapy
